Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of N-803 plus PD-1 inhibitor and docetaxel versus docetaxel in acquired ICI-resistant advanced non-small cell lung cancer
2025-521221-32-00Phase 3Authorised
- Sponsor
- ImmunityBio, Inc.
- Start
- Aug 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 22
01
Overview
Phase 3, randomised, open-label trial of nogapendekin alfa inbakicept, tislelizumab and docetaxel in non-small cell lung cancer (NSCLC) (3 arms), sponsored by ImmunityBio, Inc. Primary endpoint: Overall survival. Planned start Aug 2025; status: authorised.
02
Drugs
nogapendekin alfa inbakicepttislelizumabdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2025-521221-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521221-32-00.